semaglutide rate of weight loss dosage chart States with most people on

The EVOKE and EVOKE+ phase III trials are currently in their main treatment phase, with completion expected in September 2025

In Caucasian subjects, pulse rate increased by 14.6, 10.5, and 2.8 bpm with semaglutide 0.5, 1.0 mg, and placebo, respectively

For those whove achieved their weight loss objectives and are looking to maintain results, discussions about extending treatment or transitioning to a weight maintenance plan should take place with their doctor

Most are stamped with a 5-year expiration from manufacture

Thankfully, if you're seeking effective weight loss treatment near you, several FDA-approved medications utilize similar scientific approaches to aid in chronic weight management, and Klinic prescribes them all

During your visit, your Klinic provider will explain how oral Wegovy works and personalize your treatment plan based on your medical history and weight loss goals